An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir.
J Am Chem Soc
; 144(9): 3761-3765, 2022 03 09.
Article
in English
| MEDLINE | ID: covidwho-1713117
ABSTRACT
The Covid-19 pandemic highlights the urgent need for cost-effective processes to rapidly manufacture antiviral drugs at scale. Here we report a concise biocatalytic process for Molnupiravir, a nucleoside analogue recently approved as an orally available treatment for SARS-CoV-2. Key to the success of this process was the development of an efficient biocatalyst for the production of N-hydroxy-cytidine through evolutionary adaption of the hydrolytic enzyme cytidine deaminase. This engineered biocatalyst performs >85â¯000 turnovers in less than 3 h, operates at 180 g/L substrate loading, and benefits from in situ crystallization of the N-hydroxy-cytidine product (85% yield), which can be converted to Molnupiravir by a selective 5'-acylation using Novozym 435.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Cytidine
/
Cytidine Deaminase
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Language:
English
Journal:
J Am Chem Soc
Year:
2022
Document Type:
Article
Affiliation country:
Jacs.1c11048
Similar
MEDLINE
...
LILACS
LIS